Farther Finance Advisors LLC Has $387,000 Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Farther Finance Advisors LLC grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.6% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 628 shares of the biopharmaceutical company’s stock after purchasing an additional 55 shares during the period. Farther Finance Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $387,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Pinney & Scofield Inc. bought a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $25,000. OFI Invest Asset Management acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth $28,000. Rakuten Securities Inc. increased its holdings in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 15 shares during the period. Tompkins Financial Corp acquired a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $32,000. Finally, Curat Global LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth $32,000. Institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on REGN. Guggenheim reaffirmed a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, May 30th. The Goldman Sachs Group lowered their price objective on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating for the company in a research note on Wednesday, April 30th. Royal Bank of Canada lowered Regeneron Pharmaceuticals from a “moderate buy” rating to a “hold” rating and set a $662.00 price target on the stock. in a report on Friday, May 30th. Bank of America decreased their target price on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating for the company in a research report on Thursday, April 17th. Finally, Robert W. Baird lowered their price target on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating for the company in a research report on Friday, April 25th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $836.48.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $522.68 on Tuesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20. The business’s 50-day moving average price is $562.50 and its two-hundred day moving average price is $646.92. The company has a market capitalization of $56.43 billion, a P/E ratio of 13.65, a price-to-earnings-growth ratio of 2.34 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. During the same period in the previous year, the firm posted $9.55 EPS. The company’s quarterly revenue was down 3.7% compared to the same quarter last year. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.67%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.